Individuals can participate in the conference call by dialing 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to the “Adverum Biotechnologies Third Quarter 2019 Earnings Call.” The webcast will be accessible under Events and Presentations in the Investors section of the Company’s website. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.
About
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Vice President, Investor Relations and Corporate Communications
mlacy@adverum.com
1-650-304-3892
Media:
Account Supervisor
ccecchini@lifescipublicrelations.com
1-646-876-5196
Source: Adverum Biotechnologies, Inc.